Navigation Links
Crescendo Biologics Appoints Matthew Roe as Chief Business Officer
Date:6/22/2011

CAMBRIDGE, England, June 21, 2011 /PRNewswire/ --


 

Crescendo Biologics Limited (Crescendo) today announces the appointment of Matthew Roe as Chief Business Officer. Matthew joins Crescendo from Genzyme Corporation where he was Senior Director, Business Development & Licensing.

During a 23-year career at Genzyme, Matthew was active in licensing, alliance management, acquisition, divestment, and sales and marketing, and saw the corporation develop from an entrepreneurial start-up to a leading multi-national biotechnology company. He negotiated and managed multiple agreements for drug delivery technologies in the USA, Europe and Japan and was also a core team member on the divestment of Genzyme's Pharmaceuticals business.

Mike Romanos, CEO of Crescendo said: "Matthew's track record in business development speaks for itself. He has an exceptional depth of experience in business strategy and in implementing agreements across multiple territories. I look forward to working with him as we build on the significant advances we have made at Crescendo and position the Company to deliver real value from its world class, proprietary technology platforms."

Matthew Roe, CBO of Crescendo said: "The monoclonal antibody market is rapidly growing and continues to be a major focus for the pharma industry. Companies are searching for new platforms and approaches, particularly in the area of antibody fragments. Crescendo's technology platform, IP and insight create a strong foundation from which to make a significant impact in the field and I am delighted to be joining the Company's management team as it seeks to grow to become a leader in next-generation antibody therapeutics."

About Crescendo Biologics Ltd

Crescendo Biologics will apply highly innovative antibody fragment technologies to the development of new targeted therapeutics. The Crescendo transgenic mouse platform under development has the potential to rapidly and predictably generate high-affinity human heavy chain antibodies that readily yield VH fragments that have no requirement for humanisation. This is combined with a powerful in vitro ribosome display technology which offers significant advantages over existing approaches in antibody optimisation. VH fragments provide great flexibility as a starting point for the development of new targeted therapeutics combining the specificity and binding affinity of antibodies with certain desirable characteristics of small molecules.

Crescendo's technologies were invented by scientists at the Babraham Institute, Cambridge (UK). The Company has raised £4.5 million in seed funding from leading life sciences investors, Sofinnova Partners with Aitua, Avlar BioVentures and the Rainbow Seed Fund also participating.  http://www.crescendobiologics.com

Contacts

Mike Romanos/Amanda Bettison
Crescendo Biologics
Tel: +44(0)1223-497140
Email: mromanos/abettison@crescendobiologics.com

Chris Gardner
Citigate Dewe Rogerson
Tel: +44(0)207-638-9571
Email: chris.gardner@citigatedr.co.uk



'/>"/>
SOURCE Crescendo Biologics Limited
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Crescendo Biologics Announces First Triple Knockout Mouse
2. Crescendo Biologics Raises GBP4.5 million in Seed-Funding Led by Sofinnova Partners
3. Bacterin International Signs Its Second National GPO Contract for Bacterin Biologics and Its First For Wound Drains with ROi
4. Reportlinker Adds Whats Next in Biologics? (mAbs, rDNA, Interferons, and Other Biologics) 2011-2015
5. Pfenex Inc., Through Its Reagent Proteins Business Division, Announces Submission of Biologics Master File for Recombinant CRM197 to US FDA
6. Pioneer® Surgical Technology, Inc. Enters the Biologics Extremities and Pelvis Market
7. Aperion Biologics Initiates Clinical Trial of Z-Lig™ Device for Anterior Cruciate Ligament Reconstruction
8. New Oral Biologics Delivery Company, Entrega, Announces Strategic Partnership with Pharma
9. Reportlinker Adds Biotechnology Industry 2010 Yearbook - Top Biologics, Biosimilars, Licensing and Financing, Mergers and Acquisitions
10. Dendreon Submits Post-Approval Supplement to the PROVENGE Biologics License Application for New Jersey Manufacturing Facility
11. Reportlinker Adds Immunogenicity to Biologics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... -- Axovant Sciences Ltd. (NYSE: AXON ), ... of dementia, today announced that data on the investigational ... will be presented at the 2016 Clinical Trials in ... in San Diego . Intepirdine presentations ... complex measures of activities of daily living (ADLs) and ...
(Date:12/5/2016)... -- Research and Markets has announced the addition ... Companies" to their offering. ... , , This report ... technologies such as proteomics and metabolomics. Molecular diagnostics technologies are used ... on biomarker. Currently the most important applications of biomarkers ...
(Date:12/5/2016)... ... December 05, 2016 , ... In anticipation ... and lumbar disc production, company President, Jake Lubinski will be traveling to Germany ... AxioMed disc in Cologne and Karlsruhe to discuss the benefits of a viscoelastic ...
(Date:12/5/2016)... SAN DIEGO , Dec. 5, 2016 /PRNewswire-USNewswire/ ... treatments for congestive heart failure and other chronic ... is joining the company as Chief Financial Officer ... Renova Therapeutics with 20 years of experience in ... closely held biotech and software companies. Most recently, ...
Breaking Biology Technology:
(Date:11/30/2016)... CHICAGO , Nov. 30, 2016  higi ... a new partnership initiative targeting national brands, industry ... and reward their respective audiences for taking steps ... Since its inception in 2012, higi has built ... US, impacting over 38 million people who have ...
(Date:11/28/2016)... Nov. 28, 2016 "The ... of 16.79%" The biometric system market is in ... in the near future. The biometric system market is ... 2022, at a CAGR of 16.79% between 2016 and ... of biometric technology in smartphones, rising use of biometric ...
(Date:11/21/2016)...   Neurotechnology , a provider of high-precision ... that the MegaMatcher On Card fingerprint matching algorithm ... NIST Minutiae Interoperability Exchange (MINEX) III ... of the evaluation protocol. The ... fingerprint templates used to establish compliance of template ...
Breaking Biology News(10 mins):